Clarendon Private LLC Acquires New Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Clarendon Private LLC purchased a new stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 955 shares of the medical equipment provider’s stock, valued at approximately $498,000.

Other institutional investors have also recently made changes to their positions in the company. Berbice Capital Management LLC purchased a new position in Intuitive Surgical in the 4th quarter worth approximately $26,000. Godsey & Gibb Inc. grew its holdings in shares of Intuitive Surgical by 140.0% in the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 35 shares in the last quarter. MidAtlantic Capital Management Inc. bought a new stake in shares of Intuitive Surgical in the 3rd quarter worth about $33,000. Decker Retirement Planning Inc. purchased a new stake in Intuitive Surgical during the fourth quarter valued at approximately $36,000. Finally, Capital Performance Advisors LLP bought a new stake in Intuitive Surgical in the third quarter worth $38,000. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Trading Down 4.0 %

Shares of ISRG stock opened at $584.05 on Friday. The company has a market capitalization of $208.03 billion, a P/E ratio of 93.90, a P/E/G ratio of 5.19 and a beta of 1.39. Intuitive Surgical, Inc. has a 12-month low of $364.17 and a 12-month high of $616.00. The business’s 50 day moving average is $547.16 and its two-hundred day moving average is $504.35.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Leerink Partners boosted their target price on Intuitive Surgical from $489.00 to $502.00 in a research report on Thursday, October 17th. Erste Group Bank upgraded Intuitive Surgical from a “hold” rating to a “buy” rating in a report on Tuesday, November 19th. Evercore ISI reiterated a “cautious” rating on shares of Intuitive Surgical in a report on Friday, October 18th. Robert W. Baird boosted their price target on shares of Intuitive Surgical from $503.00 to $565.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Finally, Royal Bank of Canada increased their price objective on shares of Intuitive Surgical from $525.00 to $555.00 and gave the company an “outperform” rating in a research note on Friday, October 18th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $583.83.

Insider Activity

In other news, EVP Robert Desantis sold 188 shares of the company’s stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $506.52, for a total transaction of $95,225.76. Following the completion of the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at $2,788,899.12. This represents a 3.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jamie Samath sold 269 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $539.89, for a total transaction of $145,230.41. Following the sale, the insider now directly owns 8,757 shares of the company’s stock, valued at approximately $4,727,816.73. This represents a 2.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,475 shares of company stock worth $22,070,807 in the last quarter. Corporate insiders own 0.90% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.